(A) Follow-up | Age | OIF-RP percent (n/total) | Interfascial-RP percent (n/total) | p value |
IIEF 15–19 at 3 months | Overall | 23% (5/22) | 23% (3/13) | 0.981 |
IIEF 15–19 at 12 months | Overall | 54% (13/24) | 47% (8/17) | 0.654 |
(B) Follow-up | Age | OIF-RP percent (n/total) | Interfascial-RP percent (n/total) | p value |
IIEF ≥15 at 3 months | Overall | 47% (69/146) | 35% (35/100) | 0.056 |
<55 | 48% (10/21) | 31% (4/13) | 0.332 | |
55-65 | 49% (36/73) | 43% (20/47) | 0.469 | |
>65 | 44% (23/52) | 28% (11/40) | 0.099 | |
IIEF ≥15 at 12 months | Overall | 80% (125/157) | 57% (54/94) | <0.001 |
<55 | 96% (23/24) | 64% (7/11) | 0.012 | |
55-65 | 75% (58/77) | 61% (25/41) | 0.104 | |
>65 | 79% (44/56) | 52% (22/42) | 0.006 | |
(C) Follow-up | Age | OIF-RP percent (n/total) | Interfascial-RP percent (n/total) | p value |
IIEF ≥19 at 3 months | Overall | 31% (45/146) | 29% (29/100) | 0.760 |
<55 | 33% (7/21) | 31% (4/13) | 0.877 | |
55-65 | 32% (23/73) | 30% (14/47) | 0.842 | |
>65 | 29% (15/52) | 28% (11/40) | 0.770 | |
IIEF ≥19 at 12 months | Overall | 57% (90/157) | 46% (43/94) | 0.075 |
<55 | 75% (18/24) | 55% (6/11) | 0.226 | |
55-65 | 58% (45/77) | 44% (18/41) | 0.132 | |
>65 | 48% (27/56) | 45% (19/42) | 0.770 |